Highlights
- Sun Pharma agreed to acquire 100% stake in Innovcare Lifesciences.
- The acquisition will be completed through a cash consideration transaction.
- Sun Pharma shares traded higher by 0.52% during Monday's session.
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) has entered into an agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited, a Mumbai-based pharmaceutical company engaged in the marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.
The acquisition was disclosed by Sun Pharma under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the company, the transaction is a strategic investment aimed at strengthening its product portfolio. The acquisition does not qualify as a related-party transaction, and neither the promoter nor promoter group has any interest in the target entity.
Source: Analysis by Kalkine
Deal Structure And Key Terms
Sun Pharma will acquire the entire shareholding of Innovcare through a cash consideration transaction. The acquisition value is approximately Rs 271.2 crore. Upon completion, Sun Pharma will own 100% of Innovcare's outstanding shares.
The company stated that no governmental or regulatory approvals are required for the transaction. The acquisition is expected to be completed on or before July 31, 2026.
About Innovcare Lifesciences
Innovcare Lifesciences Private Limited was incorporated on July 21, 2014, and operates in the pharmaceuticals and healthcare sector. The company is engaged in the marketing, distribution and sale of pharmaceutical drugs, nutraceutical products and cosmeceutical products across India.
Innovcare reported revenue from operations of Rs 94.06 crore during FY26. Its revenue stood at Rs 86.09 crore in FY25 and Rs 80.93 crore in FY24.
Sun Pharma's Recent Financial Performance
For the quarter ended March 31, 2026, Sun Pharmaceutical Industries reported consolidated total income of Rs 15,503 crore, profit before tax of Rs 4,070 crore and net profit of Rs 3,018 crore.
The company remains one of India's largest pharmaceutical manufacturers with operations spanning branded formulations, generic medicines, specialty products and active pharmaceutical ingredients.
Market Reaction
Sun Pharmaceutical Industries shares traded higher on June 22, 2026, following the acquisition announcement. The stock was trading at Rs 1,850.80, up Rs 12.50 or 0.52% from the previous close of Rs 1,838.30.
The stock opened at Rs 1,845.00 and touched an intraday high of Rs 1,853.30, while the day's low stood at Rs 1,834.00. The volume-weighted average price (VWAP) was Rs 1,844.13.
Strategic Rationale
The acquisition aligns with Sun Pharma's existing presence in pharmaceuticals and healthcare. Since Innovcare operates in product categories related to pharmaceutical, nutraceutical and cosmeceutical segments, the transaction remains within Sun Pharma's broader business domain. The company has stated that the acquisition is intended to strengthen its product portfolio.
Key Risks To Watch
- Integration of acquired operations may take longer than expected.
- Product portfolio expansion may not immediately contribute to earnings.
- Competitive pressures could affect growth in acquired segments.
- Regulatory changes may impact pharmaceutical market dynamics.
Today's Share Performance
Sun Pharma shares traded in positive territory on June 22, 2026, gaining 0.52% to Rs 1,847.80 during afternoon trade.
The stock moved between Rs 1,834.00 and Rs 1,853.30 during the session after opening at Rs 1,845.00. Market participants also tracked the company's announcement regarding the proposed acquisition of Innovcare Lifesciences.
Source: TradingView
Summary
Sun Pharmaceutical Industries (NSE:SUNPHARMA) has agreed to acquire Innovcare Lifesciences for approximately Rs 271.2 crore through a cash transaction. The Mumbai-based target company generated revenue of Rs 94.06 crore in FY26 and operates in pharmaceutical, nutraceutical and cosmeceutical segments. Sun Pharma stated that the acquisition is a strategic investment intended to strengthen its product portfolio, with completion expected by July 31, 2026.
FAQs
Q: What company is Sun Pharma acquiring?
A: Sun Pharma has agreed to acquire 100% of Innovcare Lifesciences Private Limited.
Q: What is the value of the Innovcare acquisition?
A: The acquisition will be completed through a cash consideration of approximately Rs 271.2 crore.
Q: When is the acquisition expected to be completed?
A: Sun Pharma expects to complete the transaction on or before July 31, 2026.